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BACKGROUND: The higher risk of heart failure (HF) in African-American 
and Hispanic women compared with white women is related to the 
higher burden of risk factors (RFs) in minorities. However, it is unclear if 
there are differences in the association between the number of RFs for HF 
and the risk of development of HF and death within racial/ethnic groups.
METHODS AND RESULTS: In the WHI (Women’s Health Initiative; 
1993–2010), African-American (n=11 996), white (n=18 479), and 
Hispanic (n=5096) women with 1, 2, or 3+ baseline RFs were compared 
with women with 0 RF within their respective racial/ethnic groups to 
assess risk of developing HF or all-cause mortality before and after HF, 
using survival analyses. After adjusting for age, socioeconomic status, 
and hormone therapy, the subdistribution hazard ratio (95% confidence 
interval) of developing HF increased as number of RFs increased 
(P<0.0001, interaction of race/ethnicity and RF number P=0.18)—African-
Americans 1 RF: 1.80 (1.01–3.20), 2 RFs: 3.19 (1.84–5.54), 3+ RFs: 7.31 
(4.26–12.56); Whites 1 RF: 1.27 (1.04–1.54), 2 RFs: 1.95 (1.60–2.36), 
3+ RFs: 4.07 (3.36–4.93); Hispanics 1 RF: 1.72 (0.68–4.34), 2 RFs: 3.87 
(1.60–9.37), 3+ RFs: 8.80 (3.62–21.42). Risk of death before developing 
HF increased with subsequent RFs (P<0.0001) but differed by racial/ethnic 
group (interaction P=0.001). The number of RFs was not associated with 
the risk of death after developing HF in any group (P=0.25; interaction 
P=0.48).
CONCLUSIONS: Among diverse racial/ethnic groups, an increase in the 
number of baseline RFs was associated with higher risk of HF and death 
before HF but was not associated with death after HF. Early RF prevention 
may reduce the burden of HF across multiple racial/ethnic groups.
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Heart failure (HF) is one of the leading causes of morbidity and mortality in older women and is expected to rise in prevalence by 25% over the 
next 2 decades because of an aging US population.1–4 
Despite advances in therapy, HF continues to dispropor-
tionately affect African-American women compared 
with white women.2,5–7 In general, socioeconomic fac-
tors and predisposing risk factors (RFs) including hyper-
tension and diabetes mellitus have been identified as 
important contributors to this excess risk.2,6,8 Despite 
data on the incidence and prevalence of HF in women, 
which demonstrate higher risk of HF in African-Ameri-
can and Hispanic women, data examining the differen-
tial development of HF and subsequent risk of death in 
these groups are lacking.2,9
African-American and Hispanic women have higher 
prevalence of established RFs for HF, including athero-
sclerosis, hypertension, diabetes mellitus, obesity, and 
sedentary activity.2,3 The population attributable risk for 
HF based on individual RF has been widely described 
in whites, small populations of African-Americans, and 
to a lesser extent in Hispanics.2,10–12 In most studies, 
individual RFs have been associated with greater risk 
of developing HF in African-Americans and Hispanics.2 
Yet, the impact of these RFs may be much greater in 
African-American and Hispanic women who often have 
multiple RFs.2 A strong target for reducing racial/ethnic 
disparities in HF may include identifying the risk of HF 
and death before and after developing HF, dependent 
on the number of RFs.
To address these questions, we examined HF devel-
opment among African-American, white, and Hispanic 
women, using data from the WHI study (Women’s Health 
Initiative), a large population-based study of postmeno-
pausal women. Within each racial/ethnic group, we 
tested the hypothesis that compared with women with 
0 baseline RF, women with subsequently higher number 
of baseline RFs would have increased risk of developing 
HF and dying before or after developing HF.
METHODS
The data, analytic methods, and study materials are available 
to other researchers for purposes of reproducing the results or 
replicating the procedure on request and approval of the WIH 
Publications and Presentations Committee.
Data Source
The WHI is a National Heart, Lung, and Blood Institute–
supported study of US postmenopausal women followed for 
>20 years for evaluation of cardiovascular disease, cancer,
and osteoporosis.13 The original WHI population is one of
the largest female-only population studies, including 161 808
diverse racial/ethnic women who were enrolled for either ran-
domized clinical trials or an observational study.14 The study
includes self-reported medical information collected through
interviews and surveys, anthropometric measurements by
WHI personnel, and review of medical records for outcome
determination.13
Study Cohort
A subcohort of the original WHI population was selected to 
study the epidemiology of HF in postmenopausal women.5 
This sample included 44 174 postmenopausal women who 
underwent annual assessment for HF adjudication from 
baseline enrollment (1993–1998) through 2010. Race 
and ethnicity were self-identified as non-Hispanic African 
American (African-American), Hispanic, and non-Hispanic 
White (white). This population included all participants 
who were randomized to the WHI hormone therapy trial 
(n=27 347) and an oversampling of minorities to include 
all nonhormone trial African-American (n=11 880) and 
Hispanic (n=4947) women. Adjudicated HF and death were 
as of data release of December 2014. Overlapping exclu-
sions included participants of other races/ethnicities because 
of their small number of events (n=1042), self-report of HF 
or unknown HF at baseline (n=686), and participants with 
stroke attributed to atrial fibrillation because the covariates 
could not be separated (n=151). Participants with missing 
covariates (n=6768) were also excluded because the objec-
tive of this study was to assess risk based on number of RFs 
on study enrollment. Patients with missing covariates had 
no difference in incident HF or death than the final analy-
sis sample (Table I in the Data Supplement). The final sam-
ple included 35 571 participants (Figure 1). The study was 
approved by the human subjects review committee at each 
WHI participating institution, and all participants provided 
written informed consent.
Outcomes of Interest
Participants were followed until development of the following 
outcomes: incident HF requiring hospitalization and all-cause 
mortality before or after developing HF. Data on incident HF 
was abstracted annually from medical records after self-report 
of hospitalizations. A trained committee adjudicated these 
hospitalizations as definite or probable HF based on symp-
toms, physical examination, clinical data, and therapy during 
a hospitalization, which has been described elsewhere.3,15 All-
cause mortality was collected during routine WHI follow-up 
by family report and death certificate.15
WHAT IS NEW?
• Across multiple racial/ethnic groups, the number
of risk factors for heart failure (HF) is associated
with risk of developing new-onset HF and death
before HF.
• The number of risk factors for HF is not associated
with risk of death after HF.
WHAT ARE THE CLINICAL 
IMPLICATIONS?
• Public efforts should target primary prevention of
risk factors for HF, especially among African-Amer-
icans who have the highest rates of HF.
Explanatory Variables: RFs for HF
Established RFs for HF were defined per 2013 American 
College of Cardiology/American Heart Association Stage 
A classifications.3 RFs for HF included having 1+ of the fol-
lowing risks in the absence of symptomatic HF: atheroscle-
rosis (includes Stage B classifications of prior hospitalization 
for myocardial infarction because this is one of the largest 
etiologies of HF, prior percutaneous coronary intervention, 
prior coronary artery bypass graft surgery, history of carotid 
artery disease, stroke/transient ischemic attack, or peripheral 
vascular disease), diabetes mellitus (self-report of physician 
diagnosis and taking hypoglycemic medications), hyperten-
sion (self-report and taking antihypertensive medications, sys-
tolic blood pressure ≥140 mm Hg, or diastolic blood pressure 
≥90 mm Hg by measurement on enrollment), obesity (body 
mass index ≥30 kg/m2 by measurement on enrollment), and 
a recognized RFs for HF not included as Stage A: sedentary 
activity (<500 metabolic equivalent of task minute/week).16 
Metabolic syndrome was not included but can be inferred 
from the component RFs captured. Other established RFs for 
HF were excluded because they were unavailable in the WHI 
data set (cardiotoxin exposure and family history of cardio-
myopathy). No baseline cardiac imaging was available for the 
population with RFs for HF.
Statistical Analysis
Baseline patient characteristics were compared between race 
and ethnicities, using χ2 tests for categorical variables and 
analysis of variance for continuous variables. We consider 
3 outcomes: (1) time to HF from baseline, (2) time to death 
before HF, and (3) time to death after HF. For (1), time to HF 
from baseline was defined as the number of days from enroll-
ment to the first occurrence of HF. A participant was censored 
at last contact. Death was modeled as a competing risk for 
HF using Fine and Gray method, where subdistribution hazard 
was estimated.17 For (2), time to death before HF was defined 
as the number of days from enrollment to death. Follow-up 
for death was censored at last contact, and we restrict par-
ticipants to those who did not have incident HF during the 
follow-up. For (3), time to death after HF was defined as time 
from first incidence of HF to death, and participants were 
censored at last contact. Cox proportional hazard regression 
models were used for (2) and (3). Separate models were built 
for each outcome, and 3 sets of models were fitted: (1) meno-
pausal hormone therapy control: where menopausal hormone 
therapy was adjusted given increased risk of cardiovascu-
lar disease with menopausal hormone therapy irrespective 
of race/ethnicity.18; (2) age+menopausal hormone therapy: 
where age was added to the model (1); and (3) socioeconomic 
status+age+menopausal hormone therapy: where socioeco-
nomic status (education, income, and insurance) was added to 
the model (2), given known racial/ethnic differences in HF pre-
sentation.3 First, models were fitted for all the participants with 
race/ethnicity as a covariate to estimate subdistribution hazard 
ratios or hazard ratios and 95% confidence interval (CI) for the 
number of baseline RFs (1, 2, or 3+), with 0 RF as reference 
for the outcomes of interest. Then interactions between race/
ethnicity and number of baseline RFs were tested to determine 
whether risks varied by race/ethnicity. Finally, we built models 
within each race/ethnicity group to estimate subdistribution 
hazard ratios, hazard ratios, and 95% CI for the number of 
baseline RFs. Hispanic women were not assessed for all-cause 
mortality after HF because the event rate of incident HF was 
too low to yield precise estimates.
In the secondary analysis, associations between an indi-
vidual RF and outcomes were performed using model (3), 
which is described above, and by adjusting for all other RFs. 
The same outcomes were chosen: HF, death before HF, and 
death after HF. Statistical analyses were performed using 




During the enrollment period of 1993 to 1998, 35 571 
women (34% African-American, 52% white, 14% 
Figure 1. Study profile.  
The final study sample excluded 
participants with missing covariates 
and races/ethnicities that did not 
include African-American, white, and 
Hispanic women. HF indicates heart 
failure; TIA, transient ischemic attack; 
and WHI, Women’s Health Initiative.
Hispanic) were followed for the development of HF 
(Table 1). Racial/ethnic minority women were younger than 
white women (African-American mean age, 61.4; white, 
64.0; Hispanic, 60.2; P<0.0001). The majority of patients 
had 1+ RFs at baseline across race and ethnicity, but African-
Americans had the most RFs at baseline. College education 
levels were higher among African-Americans (63.2%) and 
whites (61.9%) than Hispanics (46.9%). Approximately 
half of women from all race/ethnicities had an annual 
income of <$35 000, and >80% of women from all 
race/ethnicities had some form of health insurance.
Outcomes
Over an average 13 years of follow-up, 4.4% (n=524) 
African-American, 6.3% (n=1166) white women, and 
Table 1. Baseline Characteristics











Age, y, mean (SD) 61.4 (7.1) 64.0 (7.1) 60.2 (6.8) <0.0001
No. of RFs <0.0001
 0 1315 (11.0) 4443 (24.0) 1062 (20.8)
 1 3301 (27.5) 6578 (35.6) 1872 (36.7)
 2 3859 (32.2) 4809 (26.0) 1387 (27.2)
 3+ 3521 (29.4) 2649 (14.3) 775 (15.2)
Comorbidities
Atherosclerosis 1128 (9.4) 1102 (6.0) 316 (6.2) <0.0001
 Carotid disease 34 (0.3) 47 (0.3) 11 (0.2) 0.72
 MI 341 (2.8) 358 (1.9) 48 (0.9) <0.0001
 PTCA/CABG 187 (1.6) 292 (1.6) 44 (0.9) 0.0005
 PVD 383 (3.2) 273 (1.5) 121 (2.4) <0.0001
 Stroke/TIA 446 (3.7) 408 (2.2) 135 (2.6) <0.0001
Treated diabetes mellitus 1364 (11.4) 820 (4.4) 356 (7.0) <0.0001
Hypertension <0.0001
 Never hypertensive 5470 (45.6) 12 735 (68.9) 3598 (70.6)
 Current/untreated 1118 (9.3) 1591 (8.6) 464 (9.1)
 Current/treated 5408 (45.1) 4153 (22.5) 1034 (20.3)
Obesity 6040 (50.4) 6729 (36.4) 1879 (36.9) <0.0001
Sedentary activity 7473 (62.3) 10 259 (55.5) 3070 (60.2) <0.0001
HT study arm <0.0001
 Not in HT 9769 (81.4) 0 (0.0) 3914 (76.8)
 HT 2227 (18.6) 18 479 (100.0) 1182 (23.2)
Socioeconomic variables
 Education <0.0001
 Less than HS 1289 (10.7) 911 (4.9) 1203 (23.6)
 HS/vocational 3121 (26.0) 6118 (33.1) 1502 (29.5)
 Some college 3251 (27.1) 5423 (29.3) 1248 (24.5)
 College graduate 4335 (36.1) 6027 (32.6) 1143 (22.4)
 Income <0.0001
 <$35 000 6168 (51.3) 8799 (47.6) 2899 (56.9)
 $35 000–<$50 000 2145 (17.9) 3930 (21.3) 817 (16.0)
 $50 000–<$75 000 1994 (16.6) 3109 (16.8) 657 (12.9)
 ≥$75 000 1689 (14.1) 2641 (14.3) 723 (14.2)
Any insurance 11 009 (91.8) 17 125 (92.7) 4137 (81.2) <0.0001
CABG indicates coronary artery bypass graft surgery; HF, heart failure; HS, high school; HT, hormone therapy; MI, 
myocardial infarction; PTCA, percutaneous transluminal coronary angioplasty; PVD, peripheral vascular disease; RF, risk 
factor; and TIA, transient ischemic attack.
1.8% (n=89) Hispanic women developed symptomatic 
HF requiring hospitalization. In the control which was 
adjusted for menopausal hormone therapy and fully 
adjusted models for age and socioeconomic status, 
having an additional RF was associated with a signifi-
cantly higher risk of developing HF, compared with 0 RF 
(Table 2; Figure 2; subdistribution hazard ratios [95% 
CI]: 1 RF, 1.31 [1.09–1.57]; 2 RFs, 2.11 [1.77–2.51]; 3+ 
RFs, 4.60 [3.88–5.46]; P<0.0001). An increasing num-
ber of RFs increased the risk of HF irrespective of race/
ethnicity (P=0.17 for interaction of race/ethnicity and 
number of RFs). Within each racial/ethnicity group, in 
the fully adjusted model, compared with 0 RF, sub-
distribution hazard ratios (95% CI) of developing HF 
in African-Americans for 1, 2, and 3+ RFs were 1.80 
(1.01–3.20), 3.19 (1.84–5.54), and 7.31 (4.26–12.56), 
respectively. Among whites, 1 RF (1.27 [1.04–1.54]), 2 
RFs (1.95 [1.60–2.36]), and 3+ RFs (4.07 [3.36–4.93]) 
demonstrated a higher hazard of developing HF com-
pared with 0 RF. Among Hispanics, 2 RFs (3.87 [1.60–
9.37]) and 3+ RFs (8.80 [3.62–21.42]) were associated 
with a higher risk of developing HF, but 1 RF was not 
associated with risk of HF (1.72 [0.68–4.34]).
Prior to developing HF, death occurred in 12.0% 
(n=1376) African-American, 7.2% (n=358) Hispanic, 
and 15.3% (n=2656) white women. In the fully adjust-
ed model, an additional RF modestly increased the risk 
of all-cause mortality prior to developing HF (Table 2; 
Figure 2; hazard ratios [95% CI]: 1 RF, 1.20 [1.10–1.32]; 
2 RFs, 1.43 [1.30–1.57]; 3+ RFs, 2.02 [1.83–2.23]; 
P<0.0001). An increasing number of RFs increased the 
risk of death before HF differently based on race/ethnic-
ity (P=0.001 for interaction of race/ethnicity and num-
ber of RFs). In the fully adjusted model, compared with 
0 RF, 1 RF (1.30 [1.03–1.63]), 2 RFs (1.51 [1.21–1.89]), 
and 3+ RFs (2.34 [1.88–2.91]) were associated with 
all-cause mortality prior to developing HF in African-
Americans. Among whites, 1 RF (1.19 [1.07–1.32]), 2 
Table 2. Risk of Outcomes Based on Number of RFs Compared With Reference of 0 RFs
HF* Subdistribution, 
Hazard Ratio (95% CI)
All-Cause Mortality Before HF, 
Hazard Ratio (95% CI)
All-Cause Mortality After HF, 
Hazard Ratio (95% CI)
1 RF 2 RFs 3+ RFs 1 RF 2 RFs 3+ RFs 1 RF 2 RFs 3+ RFs
All




















































































































































































































MHT control represents the unadjusted value because many patients were exposed to MHT, which has a known cardiovascular disease risk. Age+MHT and 
SES+age+MHT represent the adjusted models. Time to all-cause mortality after HF was not analyzed in Hispanics who had too few HF events. CI indicates confidence 
interval; MHT, menopausal hormone therapy; NA, not applicable; RF, risk factor; and SES, socioeconomic status.
*Death was treated as a competing risk for the time to HF.
†Significant P value <0.0001.
RFs (1.37 [1.23–1.54]), and 3+ RFs (1.78 [1.56–2.02]) 
were associated with all-cause mortality prior to devel-
oping HF. Similarly, among Hispanics, 2 RFs (2.11 [1.51–
2.94]), and 3+ RFs (2.99 [2.10–4.24]) demonstrated an 
increased risk of HF compared with 0 RF, but 1 RF was 
not associated with mortality (1.22 [0.87–1.71]).
After developing HF, 49.4% (n=259) African-Ameri-
can, 37.1% (n=33) Hispanic, and 51.1% (n=596) white 
women died. An increasing number of RFs was not 
associated with risk of death after HF (Table 2; Figure 2; 
hazard ratios [95% CI]: 1 RF, 0.99 [0.76–1.29]; 2 RFs, 
1.08 [0.84–1.40]; 3+ RFs, 1.14 [0.89–1.47]). This pat-
tern occurred irrespective of race/ethnicity (P=0.48 for 
interaction of race/ethnicity and number of RFs).
In the secondary analysis, adjusted for menopausal 
hormone therapy, age, socioeconomic status, and other 
RFs, each individual RFs was associated with increased 
risk of developing HF (Table  3). Diabetes mellitus was 
associated with significantly different risk of developing 
HF by race/ethnicity (African-American, 2.11 [1.71–2.61]; 
white, 2.78 [2.33–3.32]; Hispanic, 4.21 [2.52–7.02]; 
P=0.04 for interaction of diabetes mellitus with race/eth-
nicity; Table II in the Data Supplement). Each of the indi-
vidual RFs was associated with death before HF with the 
exception of obesity, which was associated with differ-
ent risk of death before HF across race/ethnicity (African-
American, 1.08 [0.97–1.20]; white, 0.93 [0.85–1.01]; 
Hispanic, 1.67 [1.34–2.07]; P<0.0001 for interaction of 
obesity with race/ethnicity). After HF, only atherosclerosis 
and diabetes mellitus were associated with increased risk 
of death. Obesity was associated with reduced risk of 
death after HF (0.85 [0.74–0.99]). There were no signifi-
cant differences in risk of death after HF with individual 
RF across race/ethnicity (Table II in the Data Supplement).
DISCUSSION
In one of the largest studies of a diverse racial and eth-
nic population of women, we found that an additional 
established RFs for HF was associated with significantly 
increased risk of HF and death prior to developing HF 
among African-American, Hispanic, and white women. 
Conversely, additional RFs for HF were not associated 
with increased risk of death after HF in either African-
American or white women.
Our study supports findings from smaller studies that 
address racial/ethnic differences in risk of HF based on the 
number of ideal RF.11,19 In the Jackson Heart Study of Afri-
can-Americans (n=4195), a progressively reduced risk of 
incident HF was demonstrated with an increased number 
of Life’s Simple 7 ideal RF, including ideal blood pressure, 
glucose, lipids, weight, daily exercise, balanced meals, 
and tobacco-free lifestyle.11 Similarly, in the Multi-Ethnic 
Study of Atherosclerosis (n=6506), an increased number 
of ideal RF was associated with a trend toward reduced 
incidence of HF in African-Americans, whites, and His-
panics.19 African-Americans and Hispanics demonstrated 
the greatest benefit with each additional ideal RFs.19
Figure 2. Risk of 
outcomes based on 
number of risk factors 
(RF).  
The model is fully ad-
justed for menopausal 
hormone therapy status, 
age, and socioeconomic 
status. The reference is 
0 RF. CI indicates confi-
dence interval.
The decreased risk of death with more ideal RF has 
been demonstrated in a survey study that does not 
address racial/ethnic differences.20 In the National Health 
and Nutrition Examination Survey (N=44 959), a higher 
number of Life’s Simple 7 ideal RF was associated with 
reduced risk of all-cause death.20 However, associations 
between the number of RF and risk of death after HF 
are less described in diverse racial/ethnic populations. 
Numerous studies have developed calculators to predict 
the risk of death after developing HF, but most assess 
risk based on specific types of RF, not the number of RF.3
The WHI study is unique by demonstrating the risk of 
HF and death before or after HF based on the number 
of baseline RFs. Most studies have not addressed this 
combination of progressive events within the same pop-
ulation or within diverse racial/ethnic groups. Our study 
and the Life’s Simple 7 literature suggest that preventing 
established RFs and pursuing ideal management of RFs 
may reduce racial/ethnic disparities in HF incidence and 
death prior to HF.11,19,20 However, there is a noteworthy 
distinction. The lack of an association between the num-
ber of RF and risk of death after HF in African-Americans 
and whites implies that the preventative RF target should 
occur before HF develops. Additional study is warranted 
in a larger population of Hispanic women to determine 
if the same conclusion applies.
Multiple observational studies have demonstrated the 
obesity paradox in HF, as demonstrated in this study.21,22 
Obesity was associated with increased risk of HF irrespec-
tive of race/ethnicity and increased risk of death before HF 
in Hispanics. However, obesity was protective for death 
after HF. Exercise is recommended in obese patients with 
HF because exercise is associated with improved exercise 
capacity and quality of life.3,23 The definitive trial has not 
been performed to determine if purposeful weight loss 
causes increased mortality among obese HF patients.
This study is subject to several limitations. First, 
RFs for HF did not include family history of cardiomy-














 Atherosclerosis 2.05 (1.80–2.34)* 1.56 (1.42–1.72)* 1.22 (1.03–1.45)*
 Treated diabetes 2.54 (2.23–2.90)* 2.03 (1.84–2.24)* 1.22 (1.03–1.45)*
 Hypertension 1.72 (1.56–1.91)* 1.30 (1.23–1.38)* 0.98 (0.84–1.14)
 Obesity 1.44 (1.30–1.59)* 1.03 (0.96–1.24) 0.85 (0.74–0.99)*
 Sedentary activity 1.24 (1.12–1.37)* 1.17 (1.10–1.24)* 1.15 (0.99–1.34)
African-Americans
 Atherosclerosis 1.94 (1.55–2.43)* 1.58 (1.36–1.84)* 1.16 (0.87–1.55)
 Treated diabetes mellitus 2.11 (1.71–2.61)* 1.97 (1.71–2.26)* 1.20 (0.92–1.57)
 Hypertension 2.10 (1.69–2.60)* 1.30 (1.16–1.45)* 0.96 (0.70–1.30)
 Obesity 1.58 (1.31–1.90)* 1.08 (0.97–1.20) 0.81 (0.62–1.06)
 Sedentary activity 1.30 (1.07–1.58)* 1.21 (1.08–1.35)* 0.95 (0.72–1.25)
Whites
 Atherosclerosis 2.13 (1.81–2.52)* 1.48 (1.30–1.70)* 1.26 (1.02–1.55)*
 Treated diabetes mellitus 2.78 (2.33–3.32)* 1.96 (1.68–2.30)* 1.23 (0.98–1.54)
 Hypertension 1.58 (1.39–1.78)* 1.35 (1.24–1.46)* 0.99 (0.84–1.17)
 Obesity 1.38 (1.22–1.56)* 0.93 (0.85–1.01) 0.87 (0.73–1.04)
 Sedentary activity 1.20 (1.06–1.36)* 1.14(1.05–1.23)* 1.22 (1.02–1.46)*
Hispanics
 Atherosclerosis 1.87 (0.99–3.52) 1.99 (1.45–2.74)* NA
 Treated diabetes mellitus 4.21 (2.52–7.02)* 2.56 (1.89–3.46)* NA
 Hypertension 2.13 (1.36–3.34)* 1.08 (0.86–1.35) NA
 Obesity 1.52 (0.98–2.37) 1.67 (1.34–2.07)* NA
 Sedentary activity 1.46 (0.91–2.33) 1.35 (1.08–1.68)* NA
Results are fully adjusted for menopausal hormone therapy, age, socioeconomic status, and other risk factors. 
All-cause mortality after HF was not applicable in Hispanics who had too few HF events to detect death after HF. CI 
indicates confidence interval; HF, heart failure; NA, not applicable; and RF, risk factor.
*P value <0.05.
opathy and metabolic syndrome. However, metabolic 
syndrome should be represented with the capture of 
diabetes mellitus, hypertension, and obesity. Also, 
an interdependent relationship of the individual RF 
may influence HF outcomes. For this reason, we a lso 
assessed the risk of each outcome for each individual 
RF. Second, some of the patients may have structural 
heart disease without symptoms of HF because WHI 
participants had no imaging at baseline, and patients 
with prior myocardial infarction were not excluded. Sys-
tolic dysfunction at baseline was likely low given small 
rates of myocardial infarction at baseline, but the pres-
ence of left ventricular hypertrophy was likely missed 
given high baseline prevalence of hypertension.24 
Third, incident HF only included hospitalized events 
and may underreport development of symptomatic HF. 
However, the population that is hospitalized is at the 
highest risk for death25 and thus a key group for study. 
Fourth, the socioeconomic status of participants dem-
onstrate a nonrepresentative sample of the US racial/
ethnic minorities, but this is one of the largest popula-
tion studies of diverse racial/ethnic women. Finally, the 
exact time of development of baseline RFs prior to WHI 
enrollment is not well captured for all RFs, and new 
development of some RFs during follow-up were not 
collected. However, the risk of long-term events after 
baseline provides important data that may inform pub-
lic health targets.
CONCLUSIONS
Among the WHI population of postmenopausal wom-
en, compared with 0 RF, each additional RF was associ-
ated with an increased risk of HF and death before HF 
among African-American, Hispanic, and white women. 
However, additional RFs for HF were not associated 
with increased risk of death after HF diagnosis among 
either African-American or white women. Racial/ethnic 
disparities in HF may be reduced by seeking RF preven-
tion. Further study of RF prevention interventions in 
longitudinal populations is warranted.
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